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Background/objectives: The Pediatric Proton Consortium Registry (PPCR) was 
established to expedite proton outcomes research in the pediatric population requiring 
radiotherapy. Here, we introduce the PPCR as a resource to the oncology community 
and provide an overview of the data available for further study and collaboration.
Design/methods: A multi-institutional registry of integrated clinical, dosimetric, radio-
graphic, and patient-reported data for patients undergoing proton radiation therapy was 
conceived in May 2010. Massachusetts General Hospital began enrollment in July of 
2012. Subsequently, 12 other institutions joined the PPCR and activated patient accrual, 
with the latest joining in 2017. An optional patient-reported quality of life (QoL) survey is 
currently implemented at six institutions. Baseline health status, symptoms, medications, 
neurocognitive status, audiogram findings, and neuroendocrine testing are collected. 
Treatment details of surgery, chemotherapy, and radiation therapy are documented and 
radiation plans are archived. Follow-up is collected annually. Data were analyzed 25 
September, 2017.
results: A total of 1,854 patients have consented and enrolled in the PPCR from October 
2012 until September 2017. The cohort is 55% male, 70% Caucasian, and comprised 
of 79% United States residents. Central nervous system (CNS) tumors comprise 61% 
of the cohort. The most common CNS histologies are as follows: medulloblastoma 
(n = 276), ependymoma (n = 214), glioma/astrocytoma (n = 195), craniopharyngioma 
(n = 153), and germ cell tumors (n = 108). The most common non-CNS tumors diag-
noses are as follows: rhabdomyosarcoma (n = 191), Ewing sarcoma (n = 105), Hodgkin 
lymphoma (n = 66), and neuroblastoma (n = 55). The median follow-up is 1.5 years with 
a range of 0.14 to 4.6 years.
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conclusion: A large prospective population of children irradiated with proton therapy 
has reached a critical milestone to facilitate long-awaited clinical outcomes research in 
the modern era. This is an important resource for investigators both in the consortium 
and for those who wish to access the data for academic research pursuits.
Keywords: proton, radiation, pediatrics, cancer, registry
inTrODUcTiOn
Proton therapy is a promising radiotherapy modality that should 
reduce toxicity of radiation treatment in children because of its 
superior dose placement within intended targets that spares 
surrounding normal tissues due to lack of exit dose. On aver-
age, it decreases by half the amount of normal tissue treated 
compared with modern photon techniques such as intensity 
modulated radiation therapy (IMRT) (1, 2). Lower cumula-
tive doses to surrounding normal tissue may mitigate some of 
the radiation-related acute and late side effects (3, 4), lessen 
toxicity management costs (5, 6), and increase the quality of 
life (QoL) in childhood cancer survivors (7, 8). However, the 
clinical data supporting the benefits of protons in the pediatric 
cancer population are sparse (9). To expedite health outcomes 
research in proton radiotherapy for the pediatric population, we 
established the Pediatric Proton Consortium Registry (PPCR), 
which is currently a collaboration of 13 major pediatric cancer 
centers with proton therapy. Here, we report a detailed update 
of the largest prospective cohort in existence of children treated 
with proton radiotherapy (10). We encourage partnerships 
with other investigators to answer health outcomes-based and 
comparative-effectiveness questions. We report population 
accrual progress, demographics, diagnoses, preliminary vital 
status, baseline health information, treatment details, the state 
radiographic image and radiation plan archival, and follow-up 
for this cohort. We discuss limitations of existing data and future 
strategies for optimizing outcome and toxicity reporting.
MaTerials anD MeThODs
registry Description
The PPCR is a multi-institutional registry of pediatric patients 
treated with proton radiotherapy, established to expedite 
research and better define the role of protons in pediatric 
care. The consortium of pediatric proton centers is centrally 
governed by Massachusetts General Hospital (MGH, Boston, 
MA, USA) and includes the following collaborating institutions: 
Northwestern Medicine Chicago Proton Center (Chicago, IL, 
USA), University of Florida Health Proton Therapy Institute 
(Jacksonville, FL, USA), Washington University (St. Louis, 
MO, USA), M.D. Anderson Cancer Center (Houston, TX, 
USA), University of Pennsylvania (Philadelphia, PA, USA), 
University of Washington (Seattle, WA, USA), ProCure Proton 
Therapy Center (Somerset, NJ, USA), Mayo Clinic (Rochester, 
MN, USA), Procure Proton Therapy Center (Oklahoma City, 
OK, USA), Texas Center for Proton Therapy (Irving, TX, USA), 
Maryland Proton Therapy Center (Baltimore, MD, USA), and 
Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, 
USA). Patient identification, as well as methods for consent, 
registration, registry governance, training, site communication, 
data oversight, database collection and management, qua lity 
assurance, and preliminary accrual were reported previously 
(10). Eligibility criteria include proton treatment at a PPCR-
activated institution and age <22 years at the start of radiation 
treatment. Patients are permitted to receive concurrent therapy, 
to have any type (benign or malignant) or extent (local or meta-
static) of disease treated with proton therapy, and to be synchro-
nous participants in other clinical trials, including Children’s 
Oncology Group (COG) trials.
registry infrastructure
Study data are collected and managed using REDCap (Research 
Electronic Data Capture) electronic data capture tools hosted at 
MGH (https://www.project-redcap.org/). REDCap is a secure, 
Health Insurance Portability and Accountability Act (HIPAA)-
compliant, web-based application designed to support data 
capture for research studies created at Vanderbilt University and 
supported by the NIH for continuous development and updat-
ing to provide infrastructure for clinical research. REDCap 
provides (1) an interface for validated data entry, (2) audit 
trails for tracking data manipulation and export procedures, 
(3) automated export procedures for seamless data downloads 
to common statistical packages, and (4) procedures for import-
ing data from external sources (11). The database’s branching 
logic enables only fields relevant to the previous answers to 
be presented and subsequent questions populated based on 
data input. Treatment planning computed tomography (CT) 
and radiation therapy (RT) plans are archived in DICOM and 
DICOM-RT format, respectively.
registry Quality assurance
Multiple quality assurance measures promote and enhance data 
completeness, verify data quality, and ensure continual data 
collection process improvement. Collaborators receive com-
prehensive database training prior to activation. Missing Field 
Reports are provided at regular intervals to identify critical data 
points that may have been left blank in the database. Each site is 
provided time to return to the record and enter the missing data, 
or justify why it cannot be entered. REDCap’s Data Quality Rules 
and Data Queries tools are also utilized to check for and resolve 
incorrect data, outliers, and invalid values. All sites are subject to 
annual monitoring for validation of data quality and continuity. 
Furthermore, the database configuration is routinely examined 
and adapted for capture of new or novel data relevant to the aims 
of the PPCR.
FigUre 1 | Pediatric Proton Consortium Registry (PPCR) enrollment flow diagram.
TaBle 1 | Pediatric Proton Consortium Registry patient accrual by institution 
and date of open enrollment.




Massachusetts General Hospital (Boston, MA, USA) Jul 2012 478
Northwestern Medicine Chicago Proton Center 
(Chicago, IL, USA)
Sep 2013 242
University of Florida Health Proton Therapy  
Institute (Jacksonville, FL, USA)
Nov 2013 490
Washington University (St. Louis, MO, USA) Mar 2014 81
M.D. Anderson Cancer Center (Houston, TX, USA) Jun 2014 278
University of Pennsylvania (Philadelphia, PA, USA) Jun 2014 89
University of Washington (Seattle, WA, USA) Feb 2016 41
ProCure Proton Therapy Center (Somerset, NJ, USA) Jun 2016 28
Mayo Clinic (Rochester, MN, USA) Jul 2016 58
ProCure Proton Therapy Center (Oklahoma City,  
OK, USA)
Oct 2016 13
Texas Center for Proton Therapy (Irving, TX, USA) Nov 2016 47
Maryland Proton Therapy Center (Baltimore, MD, USA) Apr 2017 9
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registry Patient-reported Outcomes 
(PrOs)
The addition of prospectively collected, PROs was offered to 
participating centers in 2015 using a previously validated health- 
related quality of life (HRQoL) survey tool (PedsQL; version 4.0; 
generic and fatigue modules). Questionnaires are administered 
on a tablet or in paper format in clinic during the first and last 
week of radiation treatment and annually thereafter electronically 
via REDCap survey sent in an e-mail, or printed on paper if the 
participant prefers. The QoL portion of the study was piloted at 
MGH before opening to collaborating centers. Five additional 
PPCR centers elected to participate in the QoL component of the 
study. Follow-up duration was calculated from the time of RT start 
for all patients with at least one documented follow-up visit after 
a minimum PPCR enrollment period of 1 year. Patients enrolled 
within 1 year were excluded from analysis since follow-up data 
are collected at 1-year intervals. Totals of certain data categories 
may not sum to 100% of cohort because of rounding, missing 
data fields, or individual data fields not yet inputted into registry.
FigUre 2 | (a) Cumulative Pediatric Proton Consortium Registry (PPCR) accrual across all sites. Accrual represents enrollment by date of consent and  
may be larger than total participants within the database at time of analysis. (B) Cumulative PPCR accrual by site.
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resUlTs
As of 25 September, 2017, 1,854 children were enrolled in the 
PPCR across 12 actively accruing proton centers nationwide. 
A thirteenth institution (Cincinnati Children’s Hospital Medical 
Center) was added prior to manuscript preparation, but com-
menced enrollment after data was frozen for analysis. Patients 
who were eligible to participate but ultimately did not enroll 
5Hess et al. PPCR Cohort
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on the study were tracked in a separate screening database at 
MGH, MD Anderson, Washington University, University of 
Florida, ProCure New Jersey, Texas Center for Proton Therapy, 
and Maryland. Approximately 347 screened patients from these 
seven institutions (mean of 50 per year) declined enrollment 
and another 26 initially declined but subsequently agreed to 
enroll (Figure 1). Accrual over time for the entire cohort and 
by institution is shown in Table 1 and Figures 2A,B. Seventy-
nine percent of the cohort resides in the United States (Table 2, 
Figures 3A,B).
Baseline information on 1,779 (96%) participants has been 
inputted into the REDCap database, including demographics, 
diagnoses, health inventory, prior radiation history, tumor-
related surgical details, diagnostic imaging reports, radiation 
treatment details, chemotherapy protocol information, and acute 
toxicity. Information from 75 (4%) patients was pending input 
completion at the time of data analysis. The cohort is slightly more 
male (55%) than female and mainly Caucasian (70%). Median 
age is about 10 years and 1 in 5 children are international refer-
rals. Detailed baseline demographic information is described 
in Table 2. The most common diagnoses are medulloblastoma, 
ependymoma, glial/astrocyte tumors, craniopharyngioma, germ 
cell (central nervous system [CNS] tumors), rhabdomyosarcoma, 
Ewing sarcoma, Hodgkin lymphoma, and neuroblastoma (non-
CNS tumors) (Table 3).
Among patients enrolled prior to September 2016, 888 (50%) 
have at least one follow-up visit documented, with a median 
follow-up of 1.5 years (range 0.1 to 4.6 years) and 765 (43%) have 
available vital status. At the time of reporting, 39 (5.1%) of enrolled 
patients were deceased as of their last follow-up (Table 4) and 28 
(72%) of these were due to the primary tumor. Three patients 
have been taken off study after not re-consenting to participate 
at age 18 (12).
At baseline, 88% of patients reported Lansky/Karnofsky 
performance status of ≥80. In total, 69% had baseline symptoms, 
most commonly focal neurologic findings or visual/ocular abnor-
malities (Table 5). Of those with available data, 14% reported at 
least one comorbidity, the most common being asthma (Table 5). 
Roughly one-third of patients reported needing support services 
or medical interventions during RT, most commonly including 
physical/occupational therapy, feeding tube placement, and 
speech or swallow intervention, which differed by institutional 
availability of supportive services. Patients commonly reported 
use of anti-emetic (27%), antibiotic (25%), and analgesic (22.5%) 
medications during treatment. Fourteen percent required pitui-
tary hormonal replacement prior to RT, which was mainly in chil-
dren with CNS tumors (18.7%) vs. non-CNS (5.8%) (p < 0.0001). 
Children with CNS tumors also received more hearing (43% vs. 
16%), neurocognitive (31% vs. 4%), and intelligence quotient 
(IQ) tests (12% vs. 2%), compared with those with non-CNS 
tumors (p < 0.0001 for all) (Table 5).
Two-thirds (66%) of enrolled patients received chemotherapy, 
with 59% reporting treatment on or per a COG investigational 
protocol. Vincristine, carboplatin, cisplatin, and temozolomide 
were the most commonly reported che motherapeutic agents for 
CNS tumors treated outside the auspices of a protocol, while 
vincristine, doxorubicin, etoposide, ifosfamide, and cyclophos-
phamide were most common for non-CNS tumors (Table  6). 
Subtotal resections were more common in children with non-
CNS tumors (73%) compared with CNS tumors (49%), while 
gross total/near resections were less common (27% vs. 51%, 
p < 0.0001) (Table 6). A majority of children received curative 
craniospinal irradiation (CSI) (17%), or involved field RT (58%) 
using mainly passive scattering (68%) vs. pencil-beam scanning 
(32%) proton therapy. More children with non-CNS tumors 
received pencil-beam scanning (39%) compared with CNS (28%) 
(p < 0.0001) (Table 6). At the time of reporting, 734 radiation 
plans for 638 patients and 1,690 diagnostic imaging studies for 
356 patients have been archived (Table 7).
DiscUssiOn
Registry enrollment of childhood cancer patients receiving pro-
ton therapy in the PPCR has reached a critical milestone of over 
1,800 children with 1.5-year median follow-up and a variety of 
disease types that can now be used for study and comparative 
effectiveness analysis with other cohorts.
Vision of the PPcr cohort
Since cancer occurs much less frequently in children than adults, 
collaboration between institutions is very helpful to more quickly 
answering important clinical research questions (13). The PPCR 
was established to expedite outcomes research in proton therapy 
by aggregating sufficient sample sizes of patients treated with 






















































































CNS, central nervous system. *Totals may not sum to 100% of cohort because of 
rounding, missing data fields, or data not yet inputted into registry. Unavailable data: 
CNS category 56/1,779 (3%), gender 5/1,779 (<1%), race 85/1,779 (5%), ethnicity 
54/1,779 (3%), and residence 157/1,779 (9%).
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FigUre 3 | (a) Home zip code of children enrolled in the Pediatric Proton Consortium Registry (PPCR) from the United States by treating institution.  
(B) Global map of children enrolled in the PPCR by treating institution.
similar tumors with proton radiotherapy across institutions. 
While the COG’s collaborative clinical trial infrastructure has 
proven itself a model of stepwise clinical advancement and 
improving cure rates across diagnoses, randomized prospective 
trials are not feasible for many important questions and scenarios 
in pediatric oncology (13, 14). Longitudinal cohort studies are 
an important adjunct to the randomized trial framework to 
help guide and improve treatments when trials are not feasible, 
appropriate, or ethical (15–19). Here we describe the PPCR 
cohort with baseline demographics, disease information, and 
initial follow-up in this relatively young cohort. The PPCR cohort 
continues to grow through enrollment and is capable of housing, 
collapsing, and categorizing the in-depth health outcomes data 
necessary to fully understand the benefits and potential pitfalls of 
proton radiotherapy employed in pediatric cancer patients. The 
database was designed comprehensively with efficient branching 
7Hess et al. PPCR Cohort
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TaBle 3 | Primary diagnosis tumor type.
intracranial and  
cns tumors





276 25.4 Rhabdomyosarcoma  
(RMS)
191 30.5
Ependymoma 214 19.7 Ewing sarcoma 105 16.8
Glial/astrocytoma 
Tumors/gangliomas
195 18 Hodgkin lymphoma 66 10.5
Craniopharyngioma 153 14.1 Neuroblastoma 55 8.8
Germ cell tumor 108 9.9 Chordoma 47 7.5
ATRT 27 2.5 Non-rms soft tissue 
sarcomas (NRSTS)
47 7.5
Meningioma 20 1.8 Carcinoma (NOS)€ 42 6.7
Vascular lesions 20 1.8 Retinoblastoma 11 1.8
Sarcoma 18 1.7 Osteosarcoma/bone 
sarcoma
11 1.6
Nerve sheath tumor 9  <1 Chondrosarcoma 8 1.3
Choroid plexus 8  <1 Esthesioneuroblastoma 6 1.0
sPineal parenchymal 
tumor
7  <1 Wilms tumor 6 1.0
Pituitary tumor 7  <1 Hemangioma 6 1.0
Neurocytoma 4  <1 Melanoma 4  <1






Other 18 1.7 Other 17 2.4
ATRT, atypical teratoid rhabdoid tumor; CNS, central nervous system; NOS, not 
otherwise specified; NRSTS, non-rhabdomyosarcomas soft tissue sarcoma; PNET, 
primitive neuroectodermal tumor; RMS, rhabdomyosarcoma. *Totals may not sum 
to 100% of cohort because of rounding, missing data fields, or data not yet inputted 
into registry. Tumor type not available in 10/1,723 (<1%) of patients with available 
diagnostic information [4/1,091 (CNS); 6/632 (non-CNS)]. €Carcinomas include adenoid 
cystic, adenocarcinoma, carcinoid, medullary, mucoepidermoid, nasopharyngeal, 
neuroendocrine, papillary, sinonasal undifferentiated carcinoma, small cell, squamous 
cell, and other.




































































































































CNS, central nervous system; FSIQ, Full Scale Intelligence Quotient; NOS, not 
otherwise specified. *Totals may not sum to 100% of cohort because of rounding, 
missing data fields, or data not yet inputted into registry. Unavailable data: performance 
status 722/1,779 (41%), comorbidities 364/1,779 (20.5%), supportive medical services 
462/1,779 (26.0%), endocrine replacement 472/1,779 (26.5%), neurocognitive 
testing 357/1,779 (20%), and audiology 354/1,779 (20%). βProportion of missing data 
unavailable for intelligent quotient. αTotals and percentages of baseline health issues 
and medication during treatment reflect occurrence within the registry and may exceed 
100 due to multiple responses per patient. ¥Common reported comorbidities include 
asthma 92/203 (45.3% of reported comorbidities), diabetes mellitus 28/203 (13.8%), 
and primary tumor of a different histology 10/203 (4.9%). §Common supportive services 
include physical/occupational therapy 182/414 (44.0% of reported services), gastric 
feeding tubes 157/414 (37.9%), and speech and swallow therapy 72/414 (17.4%). 
†Among patients with replaced hormones at the time of enrollment: thyroid 122/186 
(65.6%), desmopressin 107/186 (57.5%), cortisol 99/186 (53.2%), growth 16/186 
(8.6%), and sex hormones 19/186 (10.2%).
TaBle 4 | Clinical and vital status at last follow-up.
Total* cns non-cns
N(%)
NED/tumor controlled 559 (73.0) 364 (73.5) 195 (72)
Alive with disease 63 (8.2) 45 (9.1) 18 (6.6)
Disease progression/recurrence/
transformation
50 (6.5) 32 (6.5) 18 (6.6)
Alive, disease status unknown€ 54 (7.1) 34 (6.9) 20 (7.4)
Deceased 39 (5.1) 19 (3.8) 20 (7.4)
CNS, central nervous system; NED, no evidence of disease. *Totals may not sum to 
100% of cohort because of rounding, missing data fields, or data not yet inputted into 
registry. Unavailable data: vital status 1,014/1,779 (57%) of patients. €Alive, but no 
information about disease status available.
logic. However, the REDCap platform also allows flexible adap-
tation of data fields as needed. This registry is established to 
be a resource for participating investigators as well as outside 
researchers seeking to answer important health outcomes ques-
tions in this pediatric population.
next steps Toward comparative research
In May 2017, an External Advisory Board to the PPCR con-
vened, consisting of leaders in the pediatric oncology and 
radiation oncology communities and epidemiological research, 
and offered recommendations on next best steps to ensure the 
PPCR’s long-term investigational success. Their recommen-
dations have been incorporated into the following PPCR strate-
gic multiphase implementation plan: (1) define and fill criti cal 
missing data fields, (2) retrospectively expand the cohort to 
enroll all patients previously treated since the opening of 
8Hess et al. PPCR Cohort
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CSI, cranial spatial irradiation; IF, involved field; PF, posterior fossa; IMPT, intensity-
modulated proton therapy; RT, radiation therapy. *Totals may not sum to 100% 
of cohort because of rounding, missing data fields, or data not yet inputted into 
registry. Unavailable data: intent of RT 383/1,779 (21.5%), source/technique received 
121/1,779 (6.8%), area treated 147/1,779 (8.3%), and proton modality 399/1,779 
(22.4%). α Totals and percentages of source/technique received and area-treated 
reflect occurrence within the registry and may exceed 100 due to multiple responses 
per patient.
TaBle 6 | Information on treatments in addition to radiation.
Total* cns non-cns
chemotherapy* N(%)
Not received 476 (34.4) 389 (44.4) 86 (17.0)
Received 908 (65.6) 487 (55.6) 421 (83.0)
Patients receiving chemo 
on or per COG Trial€
498 (59.2) 249 (55.3) 249 (63.7)
common chemotherapy agents (not associated with a trial) α ¥
Vincristine 194 (56.6) 112 (55.7) 82 (57.6)
Etoposide 117 (34.1) 54 (26.9) 63 (44.4)
Cyclophosphamide 104 (30.3) 47 (23.4) 57 (40.1)
Carboplatin 83 (24.2) 64 (31.8) 19 (13.4)
Doxorubicin 77 (22.5) 7 (3.5) 70 (49.3)
Ifosfamide 67 (19.5) 17 (8.5) 50 (40.1)
Cisplatin 63 (18.4) 44 (21.9) 19 (13.4)
Temozolomide 53 (15.5) 44 (21.9) 9 (6.3)
Methotrexate 30 (8.8) 25 (12.4) 5 (3.5)
Bevacizumab 18 (5.3) 15 (7.5) 3 (2.1)
Thiotepa 14 (4.1) 14 (7.0) 0 
Actinomycin D 16 (4.7) 3 (1.5) 13 (9.2)
Irinotecan 8 (2.3) 3 (1.5) 5 (3.5)
Pre-treatment surgery results*α
Gross total (GTR) 648 (33.8) 506 (41.3) 142 (20.5)
Near total (NTR) 168 (8.8) 121 (9.9) 47 (6.8)
Subtotal (STR)/Biopsy 1,102 (57.5) 597 (48.8) 505 (72.8)
COG, Children’s Oncology Group; CNS, central nervous system; GTR, gross total 
resection; NOS, not otherwise specified; NTR, near total resection; STR, subtotal 
resection. *Totals may not sum to 100% of cohort because of rounding, missing data 
fields, or data not yet inputted into registry. Unavailable data: chemotherapy 395/1,779 
(22.2%), resection status 463/1,779 (26.0%). αTotals and percentages of common 
chemotherapy agents and pretreatment surgery results reflect occurrence within 
the registry and may exceed 100 due to multiple responses per patient. €Percent 
patients receiving chemotherapy on or per COG trial out of those who received any 
chemotherapy either before, during, or after radiation treatment (N = 908). ¥Percent  
of total, CNS, and non-CNS patients who received chemotherapy at any time point  
not associated with a COG trial.
each member institution (roughly 2006) and improve existing 
patient engagement, and (3) promote investigator-initiated use 
of the cohort to study the various facets of outcomes research 
to further promote and grow PPCR resources. These next steps 
will improve the quality of PPCR data available for comparison 
with contemporary photon cohorts to better determine who is 
getting proton RT and delineate its benefits (13, 20). This data 
resource will be made available to all academic investigators 
through partnerships with existing PPCR member institutions 
and a proposal review process similar to other cohort stud-
ies*. At present, a point of contact is available for interested 
collaborators**. 
Challenges and Modernization
The PPCR opened in 2012 with funding support from the 
Clinical Radiation Oncology Branch of National Cancer Institute 
(NCI). These funds, derived from the NCI/MGH Federal Share 
of Proton Income, are due to end in 2019. Efforts to modernize 
the registry are actively being pursued to increase efficiency and 
sustainability. The role of patient (and parent proxy) reported 
outcomes is expanding to more efficiently gather in-depth data 
from the medical record when patients self-report health changes. 
Collaborations with natural language processing (NLP) scientists 
are in process to automate and address the costs of manual data 
entry (21). Institutional processes for re-consenting minors for 
registry participation at the age of majority are being revised to 
maintain participants into adulthood (see Section “Re-Consenting 
at the Age of Majority”) (12). Integrated sharing of and enhanced 
access to electronic medical records across member institutions 
is lowering the burden of obtaining follow-up records (22). 
Ongoing improvements to the database platform are being made 
to increase efficiency in data collection. For example, analysis 
of the medication free-text data field led to the integration of 
common write-in medications in drop-down menus, including 
proton pump inhibitors (omeprazole), multivitamins, bone-
marrow stimulants (filgrastim, pegfilgrastim), melatonin, and 
anti-allergens (cetirizine, loratadine). Adding these drugs to the 
check list reduces the time required to enter data and limits the 
amount of free text to analyze. These lessons, and those learned by 
other registry efforts provide modernization strategies for other 
researchers (23).
re-consenting at the age of Majority
Pediatric Proton Consortium Registry participants are com-
monly treated at tertiary or quaternary referral proton centers 
but receive follow-up care with primary providers closer to their 
home. When participants reach the age of majority, re-consent 
for study enrollment is required. Prior Institutional Review Board 
(IRB) regulations at the lead site required the study team to make 
three attempts to reconsent the patient, and if no response was 
received, the participant was removed from the study as of their 
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18th birthday. As of December 2016, 28 participants reached 
adulthood at Mass General, 6 reconsented, 2 declined, and 20 
did not respond. The MGH IRB approved a change of this policy 
to include an HIPAA waiver for this minimal risk data collection 
study. Participants now opt in or out as adults, and if no response 
is received, they remain enrolled on the study (12). Each site 
follows its own institutional IRB guidelines about re-consenting 
patients at the age of majority.
Broader Data Quality Monitoring
Oversight monitoring of member institutions was first initiated 
in the PPCR at a level of scrutiny akin to that of a multicenter 
clinical trial and was later de-intensified to reflect the no-
more-than-minimal risk nature of the registry. Costs of annual 
travel for external patient audits grew prohibitively large with 
incremental growth to 13 member institutions. These costs, 
balanced by the need to ensure data completeness, led to the 
central PPCR team to assume multicenter responsibilities 
and remotely monitor data completeness without required 
travel. Key fields were identified and targeted for review and 
routine remote correspondence is conducted with each site for 
incomplete data inquiries. Data incompleteness was associated 
with a temporary lapse in registry funding that is actively being 
addressed (24).
cOnclUsiOn
The PPCR’s prospective cohort of children irradiated with 
modern proton therapy has reached critical mass for long-
awaited clinical outcomes research through use of the cohort’s 
open access partnership design. Modernization and recruit-
ment of investigator-initiated research is critical for the PPCR 
to publish evidence to guide treatment decisions in childhood 
cancer.
eThics sTaTeMenT
This study includes children and was reviewed and approved 
by the Institutional Review Board at Massachusetts General 
Hospital and at all 13 participating registry sites. All patients were 
consented for registry participation.
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